Long-Term Clinical, Immunologic, and Virologic Profiles of Children Who Received Early Treatment for HIV
What You Need to Know Before You Apply
What is the purpose of this trial?
IMPAACT 2028 is an observational prospective study to characterize a cohort of early treated children who may participate in future research related to HIV remission or cure. Up to approximately 250 participants will be in the study for approximately seven years. No intervention is provided in the study.
Who Is on the Research Team?
Shaun Barnabas, MD, PhD
Principal Investigator
University of Stellenbosch
Samantha Fry, MD, MMed
Principal Investigator
University of Stellenbosch
Julia Rosebush, DO, FAAP
Principal Investigator
University of Chicago
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Enrollment
Participants are enrolled in the study and baseline measurements are taken
Observational Follow-up
Participants are followed semi-annually for clinical, virologic, and immunologic evaluations
What Are the Treatments Tested in This Trial?
Interventions
- NA
Find a Clinic Near You
Who Is Running the Clinical Trial?
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator
National Institute of Mental Health (NIMH)
Collaborator